Drugs / IMOJEV
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT05568953 | Sep 2022 → Oct 2025 | Japanese encephalitis, yellow fever | Singapore General Hospital | Unknown | Met primary |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT02492165 | Jun 2015 → Mar 2016 | Japanese encephalitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01900444 | Jul 2013 → Mar 2014 | Japanese encephalitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01396512 | Jul 2011 → Mar 2013 | Japanese encephalitis | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT02526550 | Jun → Jul 2014 | encephalitis | Siriraj Hospital | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03920111 | Apr → Dec 2021 | Japanese encephalitis | University of Liverpool | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT06680128 Comparator | Feb 2025 → Jul 2026 | Japanese encephalitis | SK Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT01981967 Comparator | Nov 2013 → Apr 2015 | Japanese encephalitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMOJEV | “Participants will receive 1 dose of placebo saline and 1 dose of another active comparator (IMOJEV®, 4.0 - 5.8 log PFU) at 4-week intervals, respectively in Stage 1 and Stage 2.” NCT06680128 ↗9“Participants will receive a single dose of the Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV™) on Day 0.” NCT01396512 ↗ “Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX” NCT02526550 ↗ “This study will use live chimeric JE vaccine IMOJEV® as a tool for flavivirus epitope discovery.” NCT03920111 ↗ |
| Known as | JE-CV | “single dose of JE-CV (IMOJEV®).” PMID 29081368 ↗ Nov 2017 |
| Modality | Vaccine | “Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine” NCT01900444 ↗ |
| Route | Subcutaneous | “0.5 mL, Subcutaneous” NCT01900444 ↗ |